Clinical Trials
2 trialsNCT03820817 2026-05-26
Rifaximin in Patients With Monoclonal Gammopathy
Emory University
Phase 1 Completed
NCT04249622 2025-09-16
Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer
Mayo Clinic
Phase 2 Terminated